Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

Joanna M Wardlaw; Veronica Murray; Eivind Berge; Gregory del Zoppo; Peter Sandercock; Richard L Lindley; Geoff Cohen

doi:10.1016/S0140-6736(12)60738-7

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

Joanna M Wardlaw, Veronica Murray, Eivind Berge, Gregory del Zoppo, Peter Sandercock, Richard L Lindley, Geoff Cohen

Research output: Contribution to journal › Article › peer-review

Abstract

Recombinant tissue plasminogen activator (rt-PA, alteplase) improved functional outcome in patients treated soon after acute ischaemic stroke in randomised trials, but licensing is restrictive and use varies widely. The IST-3 trial adds substantial new data. We therefore assessed all the evidence from randomised trials for rt-PA in acute ischaemic stroke in an updated systematic review and meta-analysis.

Original language	English
Pages (from-to)	2364-72
Number of pages	9
Journal	The Lancet
Volume	379
Issue number	9834
DOIs	https://doi.org/10.1016/S0140-6736(12)60738-7
Publication status	Published - 2012

Access to Document

10.1016/S0140-6736(12)60738-7

Recombinant tissue plasminogen activator for acute ischaemic stroke
Copyright © 2012 Elsevier Ltd. All rights reserved. This document may be redistributed and reused, subject to certain conditions.
Final published version, 328 KB

MRC HUB NETWORK WORK
Murray, G. (Principal Investigator)
MRC
1/01/09 → 31/08/15
Project: Research

The third International Stroke Trial (IST-3)
Sandercock, P. (Creator), Wardlaw, J. (Creator), Lindley, R. (Creator), Cohen, G. (Creator) & Whiteley, W. (Creator), Edinburgh DataShare, 25 Jan 2021
DOI: 10.7488/ds/1350
Dataset

Cite this

@article{0cfb6b2eb7c14d04b0f024cc589dc129,

title = "Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis",

abstract = "Recombinant tissue plasminogen activator (rt-PA, alteplase) improved functional outcome in patients treated soon after acute ischaemic stroke in randomised trials, but licensing is restrictive and use varies widely. The IST-3 trial adds substantial new data. We therefore assessed all the evidence from randomised trials for rt-PA in acute ischaemic stroke in an updated systematic review and meta-analysis.",

author = "Wardlaw, {Joanna M} and Veronica Murray and Eivind Berge and {del Zoppo}, Gregory and Peter Sandercock and Lindley, {Richard L} and Geoff Cohen",

year = "2012",

doi = "10.1016/S0140-6736(12)60738-7",

language = "English",

volume = "379",

pages = "2364--72",

journal = "The Lancet",

issn = "1474-547X",

publisher = "Elsevier",

number = "9834",

}

TY - JOUR

T1 - Recombinant tissue plasminogen activator for acute ischaemic stroke

T2 - an updated systematic review and meta-analysis

AU - Wardlaw, Joanna M

AU - Murray, Veronica

AU - Berge, Eivind

AU - del Zoppo, Gregory

AU - Sandercock, Peter

AU - Lindley, Richard L

AU - Cohen, Geoff

PY - 2012

Y1 - 2012

N2 - Recombinant tissue plasminogen activator (rt-PA, alteplase) improved functional outcome in patients treated soon after acute ischaemic stroke in randomised trials, but licensing is restrictive and use varies widely. The IST-3 trial adds substantial new data. We therefore assessed all the evidence from randomised trials for rt-PA in acute ischaemic stroke in an updated systematic review and meta-analysis.

AB - Recombinant tissue plasminogen activator (rt-PA, alteplase) improved functional outcome in patients treated soon after acute ischaemic stroke in randomised trials, but licensing is restrictive and use varies widely. The IST-3 trial adds substantial new data. We therefore assessed all the evidence from randomised trials for rt-PA in acute ischaemic stroke in an updated systematic review and meta-analysis.

U2 - 10.1016/S0140-6736(12)60738-7

DO - 10.1016/S0140-6736(12)60738-7

M3 - Article

C2 - 22632907

SN - 1474-547X

VL - 379

SP - 2364

EP - 2372

JO - The Lancet

JF - The Lancet

IS - 9834

ER -

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

Abstract

Access to Document

Fingerprint

Projects

MRC HUB NETWORK WORK

Datasets

The third International Stroke Trial (IST-3)

Cite this